Please assess the completion status of the following clinical trial:

Trial Title: LIraglutide and Beta-cell RepAir (LIBRA) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and women between the ages of 30 and 75 years inclusive~* physician-diagnosed type 2 diabetes of \</= 7 years duration~* negative for anti-GAD antibodies~* on 0-2 oral anti-diabetic medications~* A1c at screening between 5.5% and 9.0% inclusive, if on oral anti-diabetic medications, or between 6.0% and 10.0% inclusive, if not on oral anti-diabetic medications~Exclusion Criteria:~* use of insulin, GLP-1 agonist, or dipeptidyl peptidase-4 (DPP-4) inhibitor~* type 1 diabetes or secondary forms of diabetes~* major illness with life expectancy \< 5 years~* involvement in another study requiring drug therapy~* hypersensitivity to insulin, liraglutide, or metformin~* renal dysfunction~* hepatic dysfunction~* history of pancreatitis~* family or personal history of Multiple Endocrine Neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma~* personal history of non-familial medullary thyroid carcinoma~* malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)~* excessive alcohol consumption~* unwillingness to undergo multiple daily insulin injection therapy~* unwillingness to perform capillary blood glucose monitoring at least 4 times per day during intensive insulin therapy~* congestive heart failure~* pregnancy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).